2016;16:275C287
2016;16:275C287. PD-L1 appearance (CHO-hPD-L1) and in handles (CHO). Specificity of [64Cu]atezolizumab was additional verified in orthotopic tumor types of individual breast cancer tumor (MDAMB231 and Amount149) and in a syngeneic mouse mammary carcinoma model (4T1). We noticed particular binding of [64Cu]atezolizumab to tumor cells in vitro, correlating with PD-L1 appearance levels. Specific deposition of [64Cu]atezolizumab […]
Recent Comments